# Phase II Study of Pandemic Influenza Vaccine

> **NCT00320346** · PHASE2 · COMPLETED · sponsor: **Seqirus** · enrollment: 400 (—)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Pandemic Influenza Vaccine

## Key facts

- **NCT ID:** NCT00320346
- **Lead sponsor:** Seqirus
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** —
- **Final completion:** 2006-09
- **Target enrollment:** 400 (—)
- **Last updated:** 2016-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00320346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00320346, "Phase II Study of Pandemic Influenza Vaccine". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00320346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*